The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
Facebook, Amazon and Alphabet, a collective $2.3 trillion in market cap, are reporting in the coming week. Here's what to watch.Trading Nationread more
The U.K. will find out who its next prime minister will be this week as voting within the U.K.'s ruling Conservative Party comes to a close.Europe Politicsread more
A settlement could reportedly come as soon as Monday.Technologyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia were lower on Monday, as shares on a new Nasdaq-style technology board on the Shanghai Stock Exchange skyrocketed on their debut day.Asia Marketsread more
Biotech stocks jumped Monday after pharmaceutical companies presented some positive drug trial results on experimental medicines that give hope for breakthrough treatments for a number of the world's toughest cancers.
The SPDR S&P Biotech XBI, an ETF that tracks the industry's biggest companies, was 1.3% higher in intraday trading, on pace for its first positive day in five. The sector was led by cancer drug company Mirati Therapeutics, which was more than 34% higher, on pace for its best day in nearly two years. Nektar Therapeutics was up 12%, on pace for its best day in a year.
Mirati's stock rose after Amgen presented positive data Monday in Chicago at the 2019 American Society of Clinical Oncology meeting.
Amgen researchers said an experimental drug targeting a mutated form of a gene known as KRAS shrank tumor growth in a small clinical trial of lung cancer patients. KRAS mutations are believed by scientists to cause cancer and is found in some patients with lung, pancreatic and colorectal cancers. That data was seen as a positive for Mirati, a smaller biotech company that is also developing drugs that target KRAS mutations.
"We think that Amgen's phase 1 results should read positive Mirati's to stock," said Varun Kumar, an analyst at Wall Street firm Cantor Fitzgerald. Amgen's result "reflect a higher likelihood of a positive readout" for Mirati's KRAS mutation-blocking drug.
Nektar Therapeutics also rallied after researchers presented data at ASCO on Saturday. The San Francisco-based biotech company said its experimental melanoma therapy, bempegaldesleukin, combined with Bristol-Myers Squibb's Opdivo helped a small number of patients with advanced skin cancer after a year.
Biotech stocks have fallen over the last three months with the broader health-care sector on concerns Washington lawmakers could make significant changes to the health-care landscape. Despite concerns, the biotech sector is up about 12% year to date compared to the 's 9% rally.
—CNBC's Gina Francolla contributed to this report.